Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Trametinib in Pediatric Refractory Histiocytosis
2024-515896-37-00Phase 2Authorised
- Sponsor
- Institute of Mother and Child
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in histiocytosis, sponsored by Institute of Mother and Child. Primary endpoints: Event-free survival (EFS), Safety of trametinib by adverse events and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
trametinib
03
Conditions
histiocytosis
Beyond the preview
Go deeper on 2024-515896-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515896-37-00.